Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoAB33
- Development stage
- Preclinical
- Lead developer
- Beijing Saisheng Pharmaceutical
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
NeoAB33 is a Class 1 biologic protein being developed by Saisheng Pharmaceutical for the treatment of hypovolemia, acute ischemic stroke, and various microcirculatory disorders. The drug functions as a kininogenase, an enzyme that releases bradykinin and lysyl-bradykinin from kininogen. These released peptides activate bradykinin B1 and B2 receptor signaling pathways, leading to immediate vasodilation and long-term angiogenesis. This mechanism increases blood flow to critical tissues, including the brain, kidneys, and heart, while also providing anticoagulation and reducing blood viscosity. Saisheng Pharmaceutical acquired the technology for NeoAB33 from Beijing Huada Protein R&D Center in June 2025 for 20 million yuan.
Beyond the preview
Go deeper on NeoAB33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoAB33.